

Anti-Human CD56 (NCAM) PE

Catalog Number :08641-60

RUO: For Research Use Only. Not for use in diagnostic procedures.

Product Information

Clone: TULY56

Format/Conjugate: PE

Concentration: 5 uL (0.06 ug)/test

Reactivity: Human

Laser: Blue (488nm)

Peak Emission: 578nm

Peak Excitation: 496nm

Filter: 585/40

Brightness (1=dim,5=brightest): 5

Isotype: Mouse IgG1, kappa

Formulation: Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, pH7.2.

Storage: Product should be kept at 2-8°C and protected from prolonged exposure to light.

Applications: FC

Description

The TULY56 monoclonal antibody specifically reacts with human CD56, or Neural Cell Adhesion molecule (NCAM). CD56 is a 140 kDa transmembrane glycoprotein also known as Leu-19 or NKH1. It is expressed on NK and NKT cells and has a role in cellular adhesion. The TULY56 antibody is reported to bind to a different epitope than the CMSSB antibody and does not block its binding.

Preparation & Storage

The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.

Application Notes

The antibody has been analyzed for quality through the flow cytometric analysis of the relevant cell type. The antibody can be used at less than or equal to 5 µL per test. A test is the amount of antibody required to stain a cell sample in the final volume of 100 µL.

References

1. Walker, W. E., Kurscheid, S., Joshi, S., Lopez, C. A., Goh, G., Choi, M., ... Zapata, H. (2015). Increased levels of macrophage inflammatory proteins result in resistance to R5-tropic HIV-1 in a subset of elite controllers. *Journal of virology*, 89(10), 5502-5514.
2. Selb, R., Eckl-Dorna, J., Neunkirchner, A., Schmetterer, K., Marth, K., Gamper, J., ... Niederberger, V. (2017). CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells. *Journal of Allergy and Clinical Immunology*, 139(1), 290-299.
3. Kim, N., Jeon, Y. W., Nam, Y. S., Lim, J. Y., Im, K. I., Lee, E. S., Cho, S. G. (2016). Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells. *Cytokine*, 78, 22-26.